Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure
Abiomed (Nasdaq: ABMD) announces that Impella RP Flex with SmartAssist has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA), the FDA’s highest level of approval, as safe and effective to treat acute right heart failure for up to 14 days. Impella RP Flex is implanted via the internal jugular (IJ) vein, which enables patient mobility, and has dual-sensor technology designed to optimize patient management.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221031005234/en/
Impella RP Flex with SmartAssist (Photo: Business Wire)
The Impella RP platform includes the world’s smallest percutaneous right heart mechanical circulatory support (MCS) technologies designed to help patients achieve native heart recovery. They do not require extracorporeal blood circulation and remain the only MCS technologies with FDA PMA indications for the treatment of right heart failure.
Key clinical benefits of Impella RP Flex include:
- Single venous access via the internal jugular (IJ) vein and 11 French (Fr) indwelling catheter, facilitating patient mobility
- Flexible cannula advanced over an extra-support guidewire, enabling ease of insertion and pump delivery
- SmartAssist dual-sensor technology with Impella Connect, providing advanced metrics to help with pump management and weaning
- Heparin-free purge, simplifying patient anticoagulant management with the use of sodium bicarbonate where heparin is of concern due to heparin intolerance or bleeding
“Impella RP Flex demonstrates Abiomed’s ongoing commitment to improving patient survival and achieving native heart recovery,” said Mark B. Anderson, MD, chairman of the department of cardiac surgery and cardiothoracic surgeon at the Heart and Vascular Hospital at HUMC/Hackensack Meridian Health.
Early identification of right heart failure or right ventricular dysfunction and early use of Impella RP is associated with significantly higher survival rates. Studies published in the Journal of Cardiac Failure and Journal of American College of Cardiology demonstrate that 37% of AMI cardiogenic shock (AMICS) patients exhibit right heart dysfunction (Lala et al.) and that right heart dysfunction is associated with three times increased risk of mortality (Mehta et al.). Data published in the Journal of Heart and Lung Transplantation shows patients who received Impella RP support within 48 hours of cardiogenic shock onset had a significantly higher survival rate than those who received delayed right-heart support (73% vs. 14%, p<0.001, Anderson et al.).
“The complexity of right ventricular failure has resulted in patients being underdiagnosed and undertreated,” said Robert Salazar, MD, an interventional cardiologist and director of cardiovascular research at Kingwood Medical Center. “Impella RP Flex is a novel tool that gives physicians the flexibility to treat this challenging patient population.”
The FDA indication for use of Impella RP Flex with SmartAssist is as follows:
The Impella RP Flex with SmartAssist System is indicated for providing temporary right ventricular support for up to 14 days in patients with a body surface area ≥1.5 m2, who develop acute right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant, or open-heart surgery.
Impella RP Flex will be introduced in the U.S. through a controlled rollout this quarter.
ABOUT IMPELLA RP WITH SMARTASSIST
Impella RP® with SmartAssist is U.S. FDA approved to treat right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant or open-heart surgery.
ABOUT ABIOMED
Based in Danvers, Massachusetts, USA, Abiomed (Nasdaq: ABMD) is a leading provider of medical technology that provides circulatory support and oxygenation. Our products are designed to enable the heart to rest and recover by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit abiomed.com.
FORWARD-LOOKING STATEMENTS
Any forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221031005234/en/
Contact information
Media:
Jenny Leary
Associate Director, U.S. Communications
+1 (978) 882-8491
jleary@abiomed.com
Investor:
Todd Trapp
Executive Vice President and Chief Financial Officer
+1 (978) 646-1680
ttrapp@abiomed.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Access Advance Announces Video Distribution Patent Pool in Response to Market Demand17.1.2025 00:00:00 CET | Press Release
Responding to growing market demand for an industry solution for codec licensing in the video distribution market, Access Advance LLC (“Advance”) is pleased to announce the launch of its Video Distribution Patent (“VDP”) Pool. The VDP Pool will build upon the success of Advance’s existing HEVC and VVC Advance Patent Pools, which are supported by a substantial majority of video codec implementers and patent owners. It will provide a single one-stop-shop license, covering internet streaming with all four of the most recently developed video codecs (i.e., HEVC, VVC, AV1, and VP9) available today, with fixed tiered pricing scaled to the size of the video distributor’s business. This structure provides simplicity and predictability to internet video distributors, allowing them to choose which codec(s) to use based on technical and business merits rather than royalty costs or the need to negotiate multiple licenses. According to Peter Moller, CEO of Advance, “In recent years, the industry ha
CoStar Group Welcomes Bidwells as a Client, Cementing CRE Analytics Leadership in the UK16.1.2025 22:07:00 CET | Press Release
CoStar Group, Inc. (NASDAQ: CSGP) (“CoStar Group,” “we” or “our”), a leading provider of online real estate marketplaces, information, and analytics in the property markets, has announced a significant new client partnership with Bidwells, a leading UK real estate advisor, specialising in science & technology, sustainability, and modern living solutions. This partnership enables Bidwells to leverage CoStar’s unrivalled commercial real estate data and analytics platform as it looks to further expand its business by tracking the market and executing strategies based on trends it identifies across multiple property sectors and regions. With access to CoStar’s extensive insights on property values, market conditions, occupancy levels, and availability, Bidwells will also enhance its ability to deliver data-driven advisory services to its clients which include many of the UK’s leading investors. “At CoStar Group, we are committed to helping our clients discover properties, gain valuable mar
FDA Authorizes All ZYN Nicotine Pouch Products Currently Marketed by Swedish Match in the U.S.16.1.2025 19:14:00 CET | Press Release
The U.S. Food and Drug Administration (FDA) today authorized ZYN nicotine pouches making ZYN the first and only authorized nicotine pouch in the United States. The FDA’s authorization of all ZYN nicotine pouches currently marketed by Swedish Match in the U.S. is an important step to protect the public health by providing better alternatives to cigarettes and other traditional tobacco products for adults 21+. “An estimated 45 million Americans regularly consume nicotine and about 30 million of them smoke, the most harmful form of nicotine consumption,” said Tom Hayes, president of Swedish Match North America, LLC. “The FDA’s decision recognizes the role that ZYN can play in the protection of the public health by helping people switch from cigarettes and other traditional tobacco products.” The FDA authorized the following products: ZYN Cool Mint 3 mg ZYN Cool Mint 6 mg ZYN Peppermint 3 mg ZYN Peppermint 6 mg ZYN Spearmint 3 mg ZYN Spearmint 6 mg ZYN Wintergreen 3 mg ZYN Wintergreen 6 mg
Alvarez & Marsal Announces 2025 Managing Director Promotions16.1.2025 17:36:00 CET | Press Release
Leading global professional services firm Alvarez & Marsal (A&M) has announced the promotion of 80 professionals, across Brazil, Canada, France, Germany, India, Italy, Spain, Sweden, United Arab Emirates, United Kingdom, and the United States, to the position of Managing Director. Tony Alvarez II and Bryan Marsal, A&M’s Co-Founders, stated, “All of our newly promoted Managing Directors embody the talent and leadership necessary to deliver exceptional results that create value for A&M’s clients. Their contributions to the growth of our firm and the clients we serve cannot be understated. From around the world and across our many lines of service, they exemplify A&M’s unwavering commitment to integrity, quality and objectivity, and are essential to the firm’s continued success and expansion.” Automotive & Industrials Russell Hunt, Houston Jack Kobus, Detroit Long Nguyen, Washington, D.C. Consumer & Retail Luis De Lencquesaing, New York Christopher Disa, New York Phani Mogalapu,Houston Co
Cognite Recognized as a Leader in Industrial Data Management Solutions16.1.2025 15:59:00 CET | Press Release
Cognite, the global leader in AI for industry, today announced it has been named a Leader in the Verdantix Green Quadrant: Industrial Data Management Solutions 2025 report for providing a market-leading DataOps and AI platform for enterprise-scale, complex Industrial Data Management (IDM) projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114915194/en/ Verdantix Green Quadrant: Industrial Data Management Solutions 2025 (Graphic: Business Wire) The report recognizes Cognite's platform, Cognite Data Fusion®, for its deeply configurable unstructured and structured industrial data orchestration, fast-paced product development, and world-class offering for complex asset-heavy industrial data and AI projects. Cognite received a perfect score for its ‘data modeling’ capabilities, the foundational element of Cognite Data Fusion® that enables Cognite customers to adapt to emerging trends and stay ahead in a rapidly evolving
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom